Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 26;12(6):1367.
doi: 10.3390/cancers12061367.

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy

Wallace Jones  1 , Kelly Griffiths  2 , Pedro C Barata  3 , Channing J Paller  2
Affiliations
Review

PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy

Wallace Jones et al. Cancers (Basel). .

Abstract

Prostate-specific membrane antigen (PSMA) has been the subject of extensive investigation in the past two decades as a promising molecular target for prostate cancer (PCa). Its appealing molecular features have enabled the development of a novel diagnostic and therapeutic-thus "theranostic"-approach to PCa. There is now substantial evidence of the high sensitivity of PSMA-targeted imaging for PCa lesions and growing evidence of the therapeutic efficacy of PSMA radioligand therapy for metastatic castration-resistant prostate cancer. This article presents a broad overview of the current status of PSMA theranostics, including current evidence, potential clinical impact, and active areas of research.

Keywords: prostate cancer; prostate specific membrane antigen; theranostics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Wright G.L., Haley C., Beckett M.L., Schellhammer P.F. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol. Oncol. 1995;1:18–28. doi: 10.1016/1078-1439(95)00002-Y. - DOI - PubMed
    1. Silver D.A., Pellicer I., Fair W.R., Heston D.W., Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 1997;3:81–85. - PubMed
    1. Minner S., Wittmer C., Graefen M., Salomon G., Steuber T., Haese A., Huland H., Bokemeyer C., Yekebas E., Dierlamm J., et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate. 2011;71:281–288. doi: 10.1002/pros.21241. - DOI - PubMed
    1. Bakht M.K., Derecichei I., Li Y., Ferraiuolo R., Dunning M., Oh S.W., Hussein A., Youn H., Stringer K.F., Jeong C.W., et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr. Relat. Cancer. 2018;26:131–146. doi: 10.1530/ERC-18-0226. - DOI - PubMed
    1. Mhawech-Fauceglia P., Zhang S., Terracciano L., Sauter G., Chadhuri A., Herrmann F.R., Penetrante R. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: An immunohistochemical study using multiple tumour tissue microarray technique. Histopathology. 2007;50:472–483. doi: 10.1111/j.1365-2559.2007.02635.x. - DOI - PubMed

LinkOut - more resources